This suggests that SR-18292 can improve sickle cell disease pathology on its own. When combined with hydroxyurea, though, SR-18292 had an even larger effect on fetal hemoglobin production. "Our ...

Recent therapies like hydroxyurea (Droxia, Bristol-Myers Squibb), the first FDA-approved drug for SCD in 1994, increase fetal hemoglobin (HbF), which, through unknown pathways, improves SCD symptoms ...

Scientists at St. Jude Children's Research Hospital and Northwestern University identified a previously unknown treatment opportunity for sickle cell disease and β-thalassemia. The discovery, ...

Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats ...

Please provide your email address to receive an email when new articles are posted on . Researchers at Boston Medical Center identified a new small molecule that could benefit people with sickle cell ...

Sickle cell disease is inherited at birth when you receive related genes from both parents. One gene usually causes sickle cell trait (SCT), which often has no health problems. The main sickle cell ...

Sickle cell disease is a hereditary condition, which means a person inherits it from their biological parents. The condition occurs when a person inherits two copies of the hemoglobin beta (HBB) gene ...

Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in ...